Last reviewed · How we verify

intracoronary infusion,

Istanbul University · FDA-approved active Small molecule Quality 0/100

The intracoronary infusion, developed by Istanbul University, is currently marketed but lacks detailed information on its mechanism, primary indication, and revenue. A key strength is the protection offered by the composition patent, which expires in 2028. The primary risk is the lack of clear competitive positioning and trial results, which may affect market adoption and investor confidence.

At a glance

Generic nameintracoronary infusion,
Also known asStreptase
SponsorIstanbul University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: